Editorial use only.
Rituximab cancer drug. Bottle containing a liquid concentrate of the cancer drug rituximab, which is marketed as MabThera. Rituximab is a monoclonal antibody used to treat B cell non-Hodgkin's lymphoma and B cell leukaemia. B cells are a type of white blood cell. The antibody works by binding to CD20 receptors on the surface of the B cells, which flags them for destruction by the body's immune system. This clears the B cells, including the cancerous cells, from the blood, allowing them to be replaced with healthy cells produced by stem cells in the bone marrow. Rituximab may also be used to treat autoimmune diseases that result from the proliferation of B cells, to help prevent rejection of transplanted organs, and also to treat rheumatoid arthritis.
Model release not required. Property release not required.